Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
BeiGene, Ltd.
- License Information
-
More Information
Article History
Accepted: 30 December 2024
First Online: 25 January 2025
Declarations
:
: Funding for this work was provided by BeiGene.
: C.M. reports no conflicts of interests. P.K. reports consultancy contracts with Sanofi, Novartis, Takeda, Merck Sharp and Dohme and Amgen to the LSE; consulting fees from PhRMA; and honoraria from EFPIA, Merck Sharp and Dohme, GlaxoSmithKline, Janssen and Amgen across other research efforts in the last 36 months. C.S. is employed with BeiGene and holds stock or stock options with BeiGene. The views expressed in this paper are expressed in her personal capacity and do not necessarily reflect those of BeiGene. No other disclosures were reported. All authors contributed to the study conception and design. The first draft of the manuscript was written by C.M., and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
: Not applicable.
: All authors provided consent for publication.
: Not applicable.
: Not applicable.
